Home / Stocks / Bliss Gvs Pharma Ltd
BLISSGVS Updated about 7 hours ago

Bliss Gvs Pharma Ltd Share Price

NSE closing price and which mutual funds hold this stock

Daily NSE closing prices — this stock isn't in the live-tracked universe yet.

NSE Close — 19 Nov 2026

₹665.35

Change

-15.0 (-2.2%)

Open

₹680.6

Prev. Close

₹680.35

Day High

₹685.4

Day Low

₹665.0

Volume Analysis

Traded

101,612

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Promoter holding is rising
  • •Strong operating margin (22.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (21.5%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹699.24 ₹692.32 ₹678.84 ₹671.92 ₹658.44 ₹651.52 ₹638.04
Fibonacci ₹692.32 ₹684.53 ₹679.71 ₹671.92 ₹664.13 ₹659.31 ₹651.52
Camarilla ₹670.96 ₹669.09 ₹667.22 ₹671.92 ₹663.48 ₹661.61 ₹659.74

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+310.43%

1 Week

+3.71%

1 Month

+8.7%

3 Months

+14.89%

6 Months

+121.52%

1 Year

+310.96%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹182.32

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.22%

Net margin 15.46% × asset turnover 0.59x × equity multiplier 1.23x

Company Overview

Sector

Healthcare

Market Cap

₹7,075 Cr

P/E (TTM)

43.5

ROE

11.8%

Book Value

₹121.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Bliss Gvs Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 64/100. The strongest factor is Financial Strength (100/100), while Valuation (18/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (22.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

64/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

62

Valuation

18

Cash Flow

52

Corporate Governance

73

Momentum

87

Institutional Ownership

41

Business Quality

76

Risk & Volatility

73

Liquidity

32

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Promoter holding has increased by 15.1% over last quarter.
  • −Stock is trading at 5.70 times its book value
  • −The company has delivered a poor sales growth of 9.94% over past five years.
  • −Company has a low return on equity of 10.2% over last 3 years.
  • −Promoters have pledged 95.8% of their holding.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

BSE and NSE each fined Rs. 1.8 lakh for Regulation 17(1) non-compliance; company has paid.

Asterisk Lifesciences received MHRA marketing authorization for Mesalazine 1g Suppositories on November 4, 2026.

The Newspaper Publication regarding Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.

Bliss GVS Pharma granted 2,95,000 stock options under ESOP 2019 on October 29, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 212 201 198 184 218 210 198 207 244 218 257 286 313
Expenses + 158 157 170 149 176 181 177 166 201 183 213 209 233
Operating Profit 54 44 28 34 41 30 21 41 43 35 44 76 81
OPM % 26.0% 22.0% 14.0% 19.0% 19.0% 14.0% 11.0% 20.0% 18.0% 16.0% 17.0% 27.0% 26.0%
Other Income + 13 5 -24 4 5 15 12 35 8 16 11 10 8
Interest 1 2 2 2 4 1 2 5 3 1 2 1 3
Depreciation 6 7 7 7 7 8 8 8 8 8 9 10 10
Profit before tax 59 40 -4 30 36 36 23 63 41 41 45 75 75
Tax % 27.0% 27.0% 24.0% 26.0% 28.0% 29.0% 29.0% 30.0% 30.0% 39.0% 18.0% 32.0% 29.0%
Net Profit + 43 29 -5 22 26 26 17 44 29 25 37 51 53
EPS in Rs 4 3 -1 2 2 2 1 4 3 2 3 5 5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 23 -2 7 15 3 5 0 13 12 4 30 38 28

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 407 547 798 815 899 689 577 747 752 770 810 927 1,074
Expenses + 304 391 596 618 739 566 471 629 634 620 683 760 838
Operating Profit 103 156 203 197 160 123 107 118 117 151 127 168 236
OPM % 25.0% 29.0% 25.0% 24.0% 18.0% 18.0% 18.0% 16.0% 16.0% 20.0% 16.0% 18.0% 22.0%
Other Income + 20 24 12 -8 35 26 20 -42 18 0 36 67 45
Interest 16 19 20 23 4 8 6 5 10 7 8 12 7
Depreciation 11 13 20 21 9 13 17 17 19 26 29 33 37
Profit before tax 96 148 175 145 182 129 104 54 106 117 126 190 236
Tax % 36.0% 32.0% 36.0% 39.0% 30.0% 26.0% 29.0% 57.0% 28.0% 30.0% 28.0% 29.0% —
Net Profit + 61 100 113 89 127 95 74 23 77 82 90 135 166
EPS in Rs 6 8 8 6 12 9 7 1 7 7 8 12 15
Dividend Payout % 12.0% 6.0% 8.0% 18.0% 8.0% 5.0% 8.0% 34.0% 7.0% 7.0% 6.0% 4.0% —
Sales growth 18 34 46 2 10 -23 -16 29 1 2 5 14 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 327 402 476 526 636 725 798 808 873 957 1,040 1,182 1,280
Borrowings + 160 132 225 118 102 126 122 109 102 100 88 22 23
Other Liabilities + 166 218 311 206 157 168 147 181 171 145 163 278 269
Total Liabilities 662 762 1,023 860 905 1,030 1,077 1,109 1,157 1,212 1,301 1,492 1,582
Fixed Assets + 234 225 305 143 146 242 234 281 379 370 406 459 471
CWIP 0 9 4 0 47 0 2 22 3 8 21 6 8
Investments 0 0 0 0 0 0 0 2 8 4 4 5 4
Other Assets + 428 527 714 717 712 788 840 803 768 830 871 1,022 1,100
Total Assets 662 762 1,023 860 905 1,030 1,077 1,109 1,157 1,212 1,301 1,492 1,582
Equity Capital 10 10 10 10 10 10 10 10 10 10 11 11 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 38 113 289 18 40 47 64 135 34 103 106 139
Cash from Investing Activity + -29 -50 -249 48 -79 -40 -45 -103 -6 -83 -75 -38
Cash from Financing Activity + -42 -40 -10 -76 17 -6 -21 -24 -25 -21 -30 -89
Net Cash Flow -34 23 30 -10 -22 0 -2 9 3 -1 0 11
Free Cash Flow 5 101 186 -7 2 -12 55 63 -59 75 33 84
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 45 101 160 29 -8 69 87 143 67 91 112 108

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 34.97% → 50.07%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 43.08% 43.71% 45.27% 46.49% 44.84% 44.98% 45.37% 45.36% 44.32% 49.15% 47.45% 35.29%
Promoters 34.97% 34.97% 34.9% 34.82% 35.1% 35.29% 35.44% 35.39% 35.36% 35.36% 35.01% 50.07%
FII 15.35% 14.74% 13.24% 12.13% 13.51% 13.18% 12.65% 13.27% 14.54% 10.45% 8.07% 5.03%
DII 6.6% 6.59% 6.58% 6.56% 6.55% 6.55% 6.54% 5.98% 5.78% 5.04% 9.46% 9.62%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Bliss Gvs Pharma Ltd (this stock) 7,075 43.5 5.5 11.8%
Kovai Medical Center & Ho 7,108 123.0 24.58 22.2%
Sanofi India Limited 7,375 16.7 8.56 47.1%
Sun Pharma Adv.res.co.ltd 6,680 4.05 4.64 279.0%
Nephrocare Health Serv L 6,500 50.8 5.46 8.83%
Suven Life Sciences Ltd 7,850 — 17.38 -81.5%
Thyrocare Tech Ltd 7,940 45.3 14.31 28.4%

Which Mutual Funds Hold Bliss Gvs Pharma Ltd?

Frequently Asked Questions about Bliss Gvs Pharma Ltd

Community Sentiment

What are other investors saying about Bliss Gvs Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.